暴露后接种改良安卡拉痘苗疫苗预防猴痘(原猴痘)的效果:法国里昂2022年6月至8月回顾性观察研究
Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
PubMed 文献 · Euro Surveill · 2022-01-01
研究纳入108名暴露于猴痘后接种一剂MVA-BN疫苗的成人,观察突破性猴痘发生情况。11例(10%)出现突破性猴痘,性暴露与突破性猴痘风险相关(p=0.0179)。接种后突破性病例的样本病毒分离率与未接种病例相似。
要点
- 108名暴露后接种MVA-BN的成人中,11例(10%)发生突破性猴痘。
- 性暴露与突破性猴痘风险相关(p=0.0179)。
- 接种后突破性病例样本的传染性病毒分离率与未接种病例相似。
核心结论
- 暴露后接种一剂MVA-BN疫苗后仍可发生突破性猴痘,性暴露与突破性猴痘风险相关。
研究设计与样本
- 回顾性观察研究,纳入108名(≥18岁)暴露于猴痘后接种一剂MVA-BN疫苗的成人。
主要发现
- 108名接种者中11例(10%)发生突破性猴痘。
- 性暴露与突破性猴痘风险相关(p=0.0179)。
- 接种后突破性猴痘病例样本的传染性病毒分离率与未接种猴痘病例相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases.
来源:Euro Surveill,查看原文。版权归原作者所有。
引用
- Merad Y, Gaymard A, Cotte L, et al. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022. Euro Surveill. 2022. PMID: 36695469. doi:10.2807/1560-7917.ES.2022.27.50.2200882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。